Literature DB >> 22821631

The plexiform neurofibroma microenvironment.

Feng-Chun Yang1, Karl Staser, D Wade Clapp.   

Abstract

Dynamic interactions between tumorigenic cells and surrounding cells, including immunomodulatory hematopoietic cells, can dictate tumor initiation, progression, and transformation. Hematopoietic-stromal interactions underpin the plexiform neurofibroma, a debilitating tumor arising in individuals afflicted with Neurofibromatosis type 1 (NF1), a common genetic disorder resulting from mutations in the NF1 tumor suppressor gene. At the tissue level, plexiform neurofibromas demonstrate a complex microenvironment composed of Schwann cells, fibroblasts, perineural cells, mast cells, secreted collagen, and blood vessels. At the cellular level, specific interactions between these cells engender tumor initiation and progression. In this microenvironment hypothesis, tumorigenic Schwann cells secrete pathological concentrations of stem cell factor, which recruit c-kit expressing mast cells. In turn, activated mast cells release inflammatory effectors stimulating the tumorigenic Schwann cells and their supporting fibroblasts and blood vessels, thus promoting tumor expansion in a feed-forward loop. Bone marrow transplantation experiments in plexiform neurofibroma mouse models have shown that tumorigenesis requires Nf1 haploinsufficiency in the hematopoietic compartment, suggesting that tumor microenvironments can depend on intricate interactions at both cellular and genetic levels. Overall, our continued understanding of critical tumor-stromal interactions will illuminate novel therapeutic targets, as shown by the first-ever successful medical treatment of a plexiform neurofibroma by targeted inhibition of the stem cell factor/c-kit axis.

Entities:  

Year:  2012        PMID: 22821631      PMCID: PMC3460056          DOI: 10.1007/s12307-012-0115-x

Source DB:  PubMed          Journal:  Cancer Microenviron        ISSN: 1875-2284


  44 in total

Review 1.  Plexiform neurofibroma genesis: questions of Nf1 gene dose and hyperactive mast cells.

Authors:  Karl Staser; Feng-Chun Yang; David W Clapp
Journal:  Curr Opin Hematol       Date:  2010-07       Impact factor: 3.284

2.  Mast cells--their presence and ultrastructural characteristics in peripheral nerve tumors.

Authors:  A Pineda
Journal:  Arch Neurol       Date:  1965-10

3.  Mast-cell stabilization to decrease neurofibroma growth. Preliminary experience with ketotifen.

Authors:  V M Riccardi
Journal:  Arch Dermatol       Date:  1987-08

Review 4.  Mast cells as sentinels of innate immunity.

Authors:  S J Galli; M Maurer; C S Lantz
Journal:  Curr Opin Immunol       Date:  1999-02       Impact factor: 7.486

Review 5.  The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others.

Authors:  S J Galli; M Tsai; B K Wershil
Journal:  Am J Pathol       Date:  1993-04       Impact factor: 4.307

6.  Possible involvement of c-kit receptor and its ligand in increase of mast cells in neurofibroma tissues.

Authors:  S Hirota; S Nomura; H Asada; A Ito; E Morii; Y Kitamura
Journal:  Arch Pathol Lab Med       Date:  1993-10       Impact factor: 5.534

7.  Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1+/- mast cells.

Authors:  Andrew S McDaniel; Jayme D Allen; Su-Jung Park; Zahara M Jaffer; Elizabeth G Michels; Sarah J Burgin; Shi Chen; Waylan K Bessler; Clemens Hofmann; David A Ingram; Jonathan Chernoff; D Wade Clapp
Journal:  Blood       Date:  2008-09-02       Impact factor: 22.113

Review 8.  It takes two to tango: mast cell and Schwann cell interactions in neurofibromas.

Authors:  David H Viskochil
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

Review 9.  CSF-1 and its receptor in ovarian, endometrial and breast cancer.

Authors:  B M Kacinski
Journal:  Ann Med       Date:  1995-02       Impact factor: 4.709

10.  Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo.

Authors:  D A Ingram; F C Yang; J B Travers; M J Wenning; K Hiatt; S New; A Hood; K Shannon; D A Williams; D W Clapp
Journal:  J Exp Med       Date:  2000-01-03       Impact factor: 14.307

View more
  11 in total

Review 1.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

2.  Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

Authors:  Brigitte C Widemann; Dusica Babovic-Vuksanovic; Eva Dombi; Pamela L Wolters; Stewart Goldman; Staci Martin; Anne Goodwin; Wendy Goodspeed; Mark W Kieran; Bruce Cohen; Susan M Blaney; Allison King; Jeffrey Solomon; Nicholas Patronas; Frank M Balis; Elizabeth Fox; Seth M Steinberg; Roger J Packer
Journal:  Pediatr Blood Cancer       Date:  2014-04-22       Impact factor: 3.167

3.  Vascular anomaly in the levator aponeurosis of neurofibromatosis type 1.

Authors:  Satoru Kase; Toshiya Shinohara; Mika Noda; Susumu Ishida; Manabu Kase
Journal:  Int J Ophthalmol       Date:  2017-04-18       Impact factor: 1.779

Review 4.  Orbital/Periorbital Plexiform Neurofibromas in Children with Neurofibromatosis Type 1: Multidisciplinary Recommendations for Care.

Authors:  Robert A Avery; James A Katowitz; Michael J Fisher; Gena Heidary; Eva Dombi; Roger J Packer; Brigitte C Widemann
Journal:  Ophthalmology       Date:  2016-11-03       Impact factor: 12.079

Review 5.  Facial plexiform neurofibroma: is it truly just skin deep?

Authors:  Wenhui Huang; Wei-Sheng Chong
Journal:  BMJ Case Rep       Date:  2013-10-07

6.  Intercostal aneurysm causing spinal cord compression in an NF1 patient.

Authors:  Varun Puvanesarajah; Ioan A Lina; Jason A Liauw; Alex L Coon; Timothy F Witham
Journal:  Eur Spine J       Date:  2013-04-19       Impact factor: 3.134

7.  Development of 3D culture models of plexiform neurofibroma and initial application for phenotypic characterization and drug screening.

Authors:  Janice M Kraniak; Anita Chalasani; Margaret R Wallace; Raymond R Mattingly
Journal:  Exp Neurol       Date:  2017-10-19       Impact factor: 5.330

Review 8.  Eliminating barriers to personalized medicine: learning from neurofibromatosis type 1.

Authors:  David H Gutmann
Journal:  Neurology       Date:  2014-06-27       Impact factor: 9.910

9.  Sphenoid Bone Pneumatisation on Lateral Cephalograms of Patients With Neurofibromatosis Type 1.

Authors:  Reinhard E Friedrich; Hannah T Scheuer; Jan F Kersten; Hanna A Scheuer
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.406

10.  Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.

Authors:  Kellie B Haworth; Michael A Arnold; Christopher R Pierson; Kwangmin Choi; Nicholas D Yeager; Nancy Ratner; Ryan D Roberts; Jonathan L Finlay; Timothy P Cripe
Journal:  Oncotarget       Date:  2017-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.